A randomized double-blind placebo-controlled study of oral coenzyme Q10 to relieve self-reported cancer-treatment-related fatigue in newly diagnosed breast cancer patients.

Lesser, G. J.; Case, L. D.; Stark, Nancy; Williford, Susan; Giguere, Jeffrey K.; Garino, A.; Naughton, Michael; Vitolins, M.; Lively, Mark O.; Shaw, Edward G.

doi:10.1200/jco.2010.28.15_suppl.9006

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other agents such as coenzyme Q10 was also examined in breast-cancer patients experienced fatigue. It showed no efficacy in reducing the fatigue and depression of breast-cancer patients [59,60].…”

Section: Discussionmentioning

confidence: 97%

Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial

et al. 2020

View full text Add to dashboard Cite

Background and objectives: Cancer-related fatigue (CRF) is one of the most prevalent complications experienced by cancer patients during and after the process of treatment. Despite conducting a lot of studies, there is no approved therapy to help manage CRF. This study aims to investigate the efficacy of bupropion on CRF. Materials and methods: In this double-blind randomized placebo-controlled clinical trial, a total of 30 eligible cancer patients suffering from fatigue were randomly divided into two groups (15 patients in each group). Bupropion was administered 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6. Fatigue as the primary outcome was measured by BFI (Brief Fatigue Inventory) and FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy) scales. Secondary outcomes included HADS (Hospital Anxiety and Depression Scale) and performance status (PS) measured by Karnofsky and ECOG (Eastern Cooperative Oncology Group) scales. Assessments were done at baseline, end of the second and sixth week. Results: There was no significant difference between placebo and bupropion at baseline and the end of second week. Significant difference was seen between two groups at the end of week six (P = 0.006 based on BFI) in favor of bupropion. In-group assessment showed improvement in fatigue levels in both groups during study time (P = 0.000 based on BFI for both bupropion and placebo). Secondary outcomes (e.g., HADS and PS) were not different at baseline and the end of second week. However, at the end of week six, the difference was significant in favor of bupropion. Conclusion: A six-week trial of bupropion reduces the CRF and improves the PS of cancer patients. Trial registration: Current Controlled Trials IRCT20090613002027N12, registration date: 2018-06-01.

show abstract

Section: Discussionmentioning

confidence: 97%

Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…2 Individuals were randomized between coenzyme Q10 combined with vitamin E (300 mg and 300 IU, respectively) or vitamin E (same dose) plus placebo. Patients were treated 24 weeks, blood levels of vitamin E and coenzyme Q10 were measured (baseline, 8, 16, 24 weeks).…”

Section: Fatiguementioning

confidence: 99%

Review from the American Society of Clinical Oncology Patient and Survivor Care Abstracts, June 4–8, 2010

Davis¹

2011

Progress in Palliative Care

View full text Add to dashboard Cite

Complementary and Alternative Treatments for the Management of Cancer-Related Fatigue

Sood

Barton

2010

Alternative and Complementary Therapies for Cancer

View full text Add to dashboard Cite

A randomized double-blind placebo-controlled study of oral coenzyme Q10 to relieve self-reported cancer-treatment-related fatigue in newly diagnosed breast cancer patients.

Cited by 7 publications

References 0 publications

Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial

Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial

Review from the American Society of Clinical Oncology Patient and Survivor Care Abstracts, June 4–8, 2010

Complementary and Alternative Treatments for the Management of Cancer-Related Fatigue

Contact Info

Product

Resources

About